Zero-Redline Thinking: How CTAide and Trust-Centered Design Are Rewriting Clinical Contracting

Author: Larry Ajuwon. RHIEOS Ventures in collaboration with Caroline Thangavelu, Engage CCS

Reading Time: 8 -10 minutes

Part 1- Why Trials Falter Before They Begin

Eleanor is energized after her second cup of ristretto. It's a few minutes before her eight o'clock clinical program-planning meeting — the one that could shape her company's future and the prospects for patients with Alzheimer's disease.

As program lead at AlphaBeta Inc., a mid-sized biotech advancing a novel cell therapy for neurological disorders, her team is responsible for both clinical studies and regulatory approval. She's a drug-development scientist with deep field experience and has seen firsthand the devastating effects of Alzheimer's and dementia on patients and their families.

It's a daunting challenge — like steering a kayak crew through turbulent waters. A global network of collaborators — medical, clinical operations, finance, legal, hospitals, service providers, patient groups, and more — each holds a stake and a say in the discovery voyage.

Eleanor's task seems deceptively simple: design a plan robust enough to meet the board's ambitious target — three clinical studies in four years.
"It's a feasible undertaking," the Chief Medical Officer had said when she asked how the numbers were set.
She nodded, though her stomach tightened. She had seen aspirational targets like this before; they often place crushing pressure on teams and invite mistakes. The ristretto steadied her nerves as she walked to the meeting room.

Study Pre-mortem

Instead of rehearsing hopeful projections, Eleanor's team turns to a pre-mortem — an exercise in imagining failure before it happens. The idea, developed by cognitive psychologist Gary Klein in 2007, is simple: assume the trial has already failed, then work backward to uncover why.

The method punctures comforting myths. It reveals that what most often delays trial start-ups isn't contracts or budgets but the overlooked fundamentals — weak protocol design, poor feasibility, hasty site selection, and relationships that were never cultivated.

A Back-to-the-Future View

As Eleanor entered the meeting room, she noticed the Chief Medic and leaders from finance, legal, and HR clustered on one side of the U-shaped table. Opposite them sat the heads of clinical and functional groups — fault lines already visible. Quality and medical experts took up the flanks, ready to tend to any "casualties."

The mood lightened when Eleanor invited everyone to share a witty line about why the program might fail.
"Every study team has a neat timeline until the redlined CTA punches it in the face," the Contracts Manager quipped.
"Ouch — I didn't see that coming," she said, smiling as the room laughed.

The exercise produced over 130 ideas, later distilled into five central themes.

It all begins with the target product profile — the document defining the desired characteristics and therapeutic purpose of the investigational drug. When that profile is incomplete or unrealistic, it ripples through to poor protocol design and limited feasibility, making it hard to recruit eligible patients or sites.

That, in turn, leads to a strenuous path through country-specific regulatory hurdles. Misalignment of goals, priorities, and capabilities among all parties quickly follows. Add in multiple systems and administrative layers, and the mix breeds delays, stress, and preventable mistakes.

Hindsight and Reality Checks

The head of Quality, quiet until now, stood and wrote two words on the flip chart: complex system. He explained that clinical trials, like startups, behave as complex adaptive systems — dynamic, nonlinear, and full of surprises. The room fell silent. Good sign, thought Eleanor.

He launched into a crisp, ten-minute TED-style talk. Silence lingered afterward. Eleanor sensed the CMO wasn't fully persuaded but had no alternative hypothesis to offer.

"Imagine a loose flotilla of kayakers from different tribes trying to navigate rapids without a skipper," the Quality head said. "A small shift can upend the entire group — or the entire trial."
"No wonder more than 90% of studies fail," someone murmured.

The group moved on to discuss how to avoid those failures.

"We need clear goals with partners — and commitment tied to the right incentives," said the Chief Medic.
"We must stay adaptable and open in how we work," added the ClinOps head, smiling wryly.
"Contracts should be tools for trust — where minds, intent, and understanding meet," said another. "Friction in contracts is often an early warning sign of deeper misalignment."
The HR lead added, "We should be as competent in collaboration as we are in negotiation."
Eleanor concluded: "We learn fast, surface risks early, and dedicate resources to fix them."
Around the room, heads nodded.

Contracts: Trust Handrails not straitjackets

Contracts are the final step before a trial can begin. Yet long before formal negotiation starts, deal-making is already underway — budget discussions, staffing debates, early talks with investigators, and informal understandings with regulators, sites, and CROs.

Even when nothing is yet signed, expectations have been set. So the later back-and-forth between legal teams and the drawn-out budget haggling should surprise no one; they often reveal gaps in trust and understanding. When sponsors, sites, and CROs can't find common ground, the discord tends to echo through every subsequent stage of the study.

Precise language on standard provisions is necessary, but collaboration thrives in the spaces between the words and numbers — in shared intent, transparency, and goodwill.

And even when trust flows freely and contracts function smoothly, studies can still fail: too few patients enroll; endpoints fall short; safety concerns outweigh benefits; or biology simply refuses to cooperate. Eleanor knew all this.

But as the team sat around the U-shaped table, sketching out what might go wrong, she felt a cautious hope. They were, at last, beginning to name the real risks.

In the next part, we'll follow their journey to design a system built to survive that uncertainty — the Zero-Redline approach.

Part 2 - Building Contracts that foster Trust and Resilience in Trials

The Contracts Manager rose to circulate what looked like one-page flyers he'd been guarding closely throughout the meeting. Legal counsel gave him a quizzical look.

He explained that the document was a short-form Clinical Trial Agreement (CTA) — written in plain language, distilled from the company's standard template and previously executed contracts. "Is it understandable, flexible, balanced, and usable?" he asked. "Does it cover the essentials — scope, risk, payment, and data rights?"

Legal responded first: the form didn't comply with company policy, and most sites would never agree to it. The manager smiled. "That's exactly the point," he said. "If contracts were designed this way — so clear and balanced that no one felt compelled to redline them — we'd eliminate months of negotiation. A CTA now takes three to four months to finalize; an amendment can take an additional one to two months. We are also dissatisfied with the quality of our agreements and collaborations, regardless of scope, including CRO, labs, technical services, and partnerships. These are all issues that contribute to the failings.

"Imagine if the design-for-trust template, backed by coherent policies, guidelines, and playbooks, could remove all that pain."

Silence settled in the room. Eleanor sensed that the Zero-Redline idea had landed. It was, in essence, a proposal to redesign the contract itself — not as a legal weapon, but as a tool for trust and collaboration.

Why Contracts Fail

Weeks passed after the pre-mortem, and turning insights into an agreed action plan proved harder than expected. Getting the new approach approved across departments proved to be a challenge. The issue eventually reached the executive level, since it implied a review of corporate policy.

The Contracts Manager's radical one-page CTA was set aside, but his questions had opened a door. Teams began combing through legacy and active contracts, analyzing negotiation logs and outcomes to trace the root causes of contracting failure.

Painful stories surfaced.
In one study, site activation was delayed for weeks — patients waited — because parties couldn't agree on the indemnification cap. In another, disputes erupted over whether the budget included patient expenses for unscheduled visits. Each story revealed patterns.

From these reviews, several recurring factors emerged:

- Disconnect between policy and practice: A gap often exists between the organization's stated values and the operational culture embedded in SOPs, playbooks, and templates.
- Misaligned priorities: Stakeholders — sponsors, sites, CROs — enter negotiations with differing motives, leading to friction and miscommunication.
- Imbalanced standard terms: Boilerplate clauses on risk, rights, and obligations are frequently perceived as one-sided, prolonging negotiation cycles.
- Lack of clarity in key elements: Objectives, scope, performance metrics, logistics, and payment terms are sometimes vague or inconsistently applied.
- Inefficient review cycles: Multiple drafting rounds erode trust, enthusiasm, and timelines.
- Non-standard handling of sensitive clauses: Intellectual property, data ownership, publication rights, and indemnification often deviate from accepted norms, inviting disputes.
- Overly rigid templates and legalistic language: Dense templates discourage comprehension and invite transactional rather than systemic problem-solving.
- Poorly aligned incentives: Contractual goals seldom reinforce collaborative performance or mutual success metrics.

The conclusion was uncomfortable but clear: the system itself was failing.

Turning Foresight into Action

The pre-mortem had revealed that most breakdowns fell into three systemic categories:

1. Governance — the overarching policies and frameworks governing contracts.
2. Guidelines and Tools — including playbooks, negotiation procedures, and review practices.
3. Goals and Roles — clarity of objectives, responsibilities, and performance measures.

The team's insight was that contracting could not be fixed in fragments. It required an integrated redesign — a cultural and procedural recalibration.

They began with governance. Contracting policies were revised to align with internationally recognized frameworks such as ISO 9001 (quality management) and ISO 44001 (collaborative business relationships). This provided a common language for consistency, transparency, and trust.

Next came tools. The group introduced practical mechanisms to assess whether contracts were balanced, usable, and fit for purpose.
A Contract Review Checklist helped teams spot red flags early. An internal CTA Inventory and Assessment Tool (aptly named CTAide) created visibility across studies, showing where negotiations tended to stall and why.

Templates and playbooks were rewritten with a simple mandate: make them usable.
The goal wasn't to simplify the law, but to make the legal structure comprehensible to those executing it. Each clause now carried guidance notes — plain-language explanations of intent and risk implications.

Finally, the focus turned to people. Policies and tools were necessary, but capability was the multiplier.

Eleanor championed a series of cross-functional training sessions that simulated contract negotiations under realistic time pressure. The exercise built fluency, empathy, and systems thinking — qualities no software could automate.

"We're not just contracting faster," she told the team. "We're contracting smarter."

Trust Tools as Guidelines

Two innovations emerged from this work: the Clinical Trial Agreement Inventory and CTAide — a digital companion.

Clinical Trial Agreement Inventory
Developed by ENGAGE Clinical Contract Solutions, the inventory provides a structured reference for contract managers and lawyers developing or reviewing CTAs in partnership with sponsors or CROs. It highlights essential elements — scope, risk, governance, payment, data — and common pitfalls encountered in negotiation.
It helps reviewers identify what's covered, what's missing, and what requires escalation or reinterpretation.

CTAide™
Created by RHIEOS Ventures in collaboration with ENGAGE CCS, CTAide translates the inventory into an interactive, web-based tool.
It analyzes agreements for completeness, balance, and usability — highlighting clauses that may be one-sided or vague. It can quantify risk exposure and visualize how balanced an agreement is between the sponsor, CRO and the institution.

Together, these tools turned the Zero-Redline aspiration into something tangible — a trust instrument that could evolve with each negotiation.

Contracts as the Capstone of Collaboration

Weeks later, as Eleanor paused by the watercooler before another program meeting, a milestone echoed in her mind: forty-five days to site activation; contracts signed on the final day.

The weight was real — and not hers alone. She knew that even with everything in place, the trials could falter.

But the traces it leaves behind — a shard of knowledge about disease progression, a clue to biology's hidden logic, a refinement of what will not work.
Each study provides a piece to solving the Alzhiemer's puzzle.

The contract, Eleanor realized, is more than a legal checkpoint. It is both signal and artifact — evidence that trust has been forged and alignment reached.
Like a capstone set atop an arch, it completes a structure that, though fragile, points forward. Beneath that arch lies not just the promise of one therapy, but the shared hope of cures yet to come.

She took her glass of water, smiled at the doodle in her notebook — a timeline being knocked over by a redline — and felt, for once, that the team had built a plan resilient enough to withstand reality.

Part 3 - Online Chat/Webinar

Building Trust, Accelerating Trials: A Fireside Chat on Clinical Trial Contracting

Goal
To explore why clinical trial contracting so often becomes a hidden bottleneck—and how trust-centered design, better systems, and practical tools can accelerate study timelines.

Target Audience
Clinical operations professionals, contract managers, legal teams, outsourcing leads, and biotech/pharma executives.

Format
Live moderated fireside conversation between:

- Larry Ajuwon – RHIEOS Ventures (Moderator)
- Caroline Thangavelu – Founder, Engage Clinical Contract Solutions (Seasoned CTA Professional)

With live audience polls, chat prompts, and open discussion.

I. Introduction – Setting the Scene (5 minutes)

Welcome & informal introductions

Larry briefly introduces himself and Caroline, focusing on real-world experience rather than formal CVs.

Opening hook

"Every study team has a beautiful timeline… until the first redlined CTA punches it in the face."

Context

- Why contracting quietly shapes trial success or failure
- Why this session is a conversation, not a lecture or product pitch

Audience interaction (live poll)
What delays your trials most often?

II. Opening Conversation – Where Things Really Go Wrong (10 minutes)

Larry → Caroline

Key questions

- "When did you first realize contracting itself had become part of the problem?"
- "What do most teams underestimate about negotiations?"

Themes explored

- Endless redlines
- Policy vs. operational reality
- Misaligned incentives between sponsors, CROs, and sites
- Negotiating positions instead of solving problems

Audience chat prompt

"In one sentence: which clause or issue causes the longest delays in your experience?"

Selected responses are discussed live.

III. Key Issues & Challenges – From Symptoms to Systems (10 minutes)

Conversation prompts

1. Disconnects

"We often see a gap between policy and practice. Where does this gap do the most damage—and how can teams realistically close it?"

2. Standard Terms & Legal Language

"Why do templates become battlegrounds, and how can contracts be made clearer and more balanced without weakening legal protection?"

3. Process & Sensitive Clauses

"IP, indemnification, liability caps—why do these always stall deals, and what actually helps resolve them faster?"

Audience invited to add short experiences via chat.

IV. Lessons Learned & Best Practices (10 minutes)

Conversation focus

From transactional to relational

"What does a 'trust-building contract' look like in practice?"

Foresight & planning

"From your experience, what small changes produced the biggest improvements?"

Governance, tools & skills

"If you could redesign one thing—policy, templates, or training—what would it be?"

Audience participation

Short live reflections or chat input on what has worked in their organizations.

V. **CTAide Demonstration** – From Insight to Tool (5 minutes)

Transition story

Larry briefly explains how:

- Caroline's frontline contracting experience led to the Clinical Trial Agreement Inventory
- This was translated into CTAide to make "what good looks like" visible and operational

Short demo

- Completeness & balance assessment
- Flagging vague or one-sided clauses
- Risk distribution visualization

Caroline comments on real-world usage

Audience question:

"Would this kind of visibility change how your teams negotiate?"

VI. Takeaways, Call to Action & Q&A (5 minutes)

Joint takeaways (Larry & Caroline)

1. Contracting is part of trial design—not administration.
2. Trust is engineered through systems, not goodwill alone.
3. Tools + governance + skills outperform heroic individual effort.

Call to action

- Rethink how CTAs are designed and reviewed
- Explore structured approaches (including CTAide)
- Continue the conversation beyond the session

Open Q&A

Part 1 - Why Trials Falter Before They Begin

Clinical trials are complex adaptive systems with 90%+ failure rates

Most delays stem from overlooked fundamentals: weak protocol design, poor feasibility, hasty site selection, and weak relationships

A pre-mortem exercise revealed 5 central themes of failure, rooted in incomplete target product profiles, misaligned goals, and multiple administrative layers

Contracts are trust handrails, not straitjackets—friction in contracts signals deeper misalignment

Success requires clear goals, adaptability, competent collaboration, and early risk surfacing

Part 2 - Building Contracts that Foster Trust and Resilience

The Zero-Redline approach redesigns contracts as trust tools, not legal weapons.

Root causes of contracting failure: policy-practice gaps, misaligned priorities, imbalanced terms, unclear objectives, inefficient reviews, non-standard sensitive clauses, rigid templates, and poorly aligned incentives.

Integrated Redesign for Success

Solution requires integrated redesign across 3 systemic categories:

Governance

Clear decision-making frameworks and accountability.

Guidelines & Tools

Practical guides and digital solutions to streamline processes.

Goals & Roles

Defined objectives and responsibilities for all stakeholders.

Innovations for Trust-Centered Contracting

Clinical Trial Agreement Inventory

A comprehensive reference framework to standardize and assess agreement terms.



CTAide

A digital tool for analyzing completeness, balance, and usability of clinical trial agreements, offering risk distribution visualization.

> Contracts serve as capstones of collaboration—signals that trust has been forged and alignment reached.

Part 3 - Building Trust, Accelerating Trials: A Fireside Chat

Format

Live moderated conversation between Larry Ajuwon (RHIEOS Ventures) and Caroline Thangavelu (Founder, Engage Clinical Contract Solutions)

Core Themes Explored

Where contracting becomes a bottleneck, policy vs. operational reality, misaligned incentives, and endless redlines

Key Discussion Areas

Disconnects between policy and practice, standard terms and legal language clarity, and sensitive clauses (IP, indemnification, liability)

Practical Focus

Moving from transactional to relational contracting, identifying small changes with big impact, and redesigning governance, templates, and training

CTAide Demonstration

Showing completeness & balance assessment, flagging vague clauses, and risk distribution visualization

Call to Action

Rethink CTA design, explore structured approaches, and continue the conversation



Key Takeaways - Zero-Redline Thinking in Action

Contracting is part of trial design—not administration. It's a capstone that signals alignment and trust.

Trust is engineered through systems, not goodwill alone. Governance, tools, and skills outperform heroic individual effort.

Clinical trials behave as complex adaptive systems—small shifts can upend entire programs. Foresight and early risk surfacing are critical.

The Zero-Redline approach transforms contracts from legal weapons into collaboration tools by redesigning them for clarity, balance, and usability.

Success requires integrated change: aligned policies, practical tools (like CTAide), cross-functional training, and a cultural shift from negotiation to problem-solving.

Real impact: 45 days to site activation with contracts signed on the final day—demonstrating that trust-centered design accelerates timelines.

Connect With Us

Learn more about Zero-Redline Thinking and how CTAide can transform your clinical trial contracting process.

Key People Behind Zero-Redline Thinking

Larry Ajuwon

Founder, RHIEOS Ventures Ltd

- 25+ years in biopharmaceuticals, MedTech, and diagnostics
- Expert in R&D, clinical programs, and clinical trial negotiations

LinkedIn: linkedin.com/in/larryajuwon/

Caroline Thangavelu

Founder, Engage Clinical Contract Solutions (Engage CCS)

- 15+ years of clinical contracting experience
- Specialist in simplifying clinical trial agreements and accelerating negotiations

LinkedIn: linkedin.com/in/carolinethangavelu/

Resources

Explore our partner organizations and their solutions:

Dealligence

Website: www.dealligence.com

Focus: Clinical Trial Agreement Inventory and strategic deal management for clinical development

Engage Clinical Contract Solutions (Engage CCS)

Website: www.engageccs.com

CTAide™

Website: www.ctaide.com

Tool: Clinical Trial Agreement Inventory Assessment Aide

For more information on the Zero-Redline approach and to schedule a consultation, visit any of these resources or reach out directly.